Report of Foreign Issuer (6-k)
May 18 2017 - 7:35AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May 2017
Commission
File Number
1-15182
DR.
REDDYS LABORATORIES LIMITED
(Translation of registrants name into English)
8-2-337,
Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by
check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Form
20-F
☒
Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ______
Note:
Regulation
S-T
Rule 101(b)(1) only permits the submission in paper of a Form
6-K
if submitted solely to provide an attached annual report to security holders.
Indicate by check
mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ______
Note:
Regulation
S-T
Rule 101(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form
6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
☐ No ☒
If Yes is marked, indicate below the file number assigned to registrant in connection with Rule
12g3-2(b):
82-________.
EXHIBITS
|
|
|
Exhibit Number
|
|
Description of Exhibits
|
|
|
99.1
|
|
Press Release, Dr. Reddys Laboratories announces USFDA approval for the launch of Doxorubicin Hydrochloride Liposome Injection in the U.S. Market, dated May 17, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
DR. REDDYS LABORATORIES LIMITED
(Registrant)
|
|
|
|
Date: May 18, 2017
|
|
By:
|
|
/s/ Sandeep Poddar
|
|
|
|
|
Name:
|
|
Sandeep Poddar
|
|
|
|
|
Title:
|
|
Company Secretary
|
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2024 to May 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2023 to May 2024